WO2002070011A3 - Treatment of ppar mediated diseases - Google Patents

Treatment of ppar mediated diseases Download PDF

Info

Publication number
WO2002070011A3
WO2002070011A3 PCT/US2002/003017 US0203017W WO02070011A3 WO 2002070011 A3 WO2002070011 A3 WO 2002070011A3 US 0203017 W US0203017 W US 0203017W WO 02070011 A3 WO02070011 A3 WO 02070011A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mediated diseases
ppar
ppar mediated
compound
Prior art date
Application number
PCT/US2002/003017
Other languages
French (fr)
Other versions
WO2002070011A2 (en
Inventor
Timothy Mark Willson
Original Assignee
Smithkline Beecham Corp
Timothy Mark Willson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Timothy Mark Willson filed Critical Smithkline Beecham Corp
Priority to US10/470,886 priority Critical patent/US20040138094A1/en
Priority to AU2002243778A priority patent/AU2002243778A1/en
Priority to EP02709285A priority patent/EP1357914A2/en
Publication of WO2002070011A2 publication Critical patent/WO2002070011A2/en
Publication of WO2002070011A3 publication Critical patent/WO2002070011A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

This invention provides a method for identifying a treatment regime for a compound or composition effective in treating a PPAR mediated disease or condition. The method includes determingin a treatment regime for the compound or composition that causes expression of a surrogate market for PPAR delta activity whereby the determined dose and route of administration identifies an effective treatment protocol.
PCT/US2002/003017 2001-02-02 2002-01-31 Treatment of ppar mediated diseases WO2002070011A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/470,886 US20040138094A1 (en) 2002-01-31 2002-01-31 Treatment regimes
AU2002243778A AU2002243778A1 (en) 2001-02-02 2002-01-31 Treatment of ppar mediated diseases
EP02709285A EP1357914A2 (en) 2001-02-02 2002-01-31 Treatment of ppar mediated diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26639301P 2001-02-02 2001-02-02
US60/266,393 2001-02-02

Publications (2)

Publication Number Publication Date
WO2002070011A2 WO2002070011A2 (en) 2002-09-12
WO2002070011A3 true WO2002070011A3 (en) 2003-04-24

Family

ID=23014384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003017 WO2002070011A2 (en) 2001-02-02 2002-01-31 Treatment of ppar mediated diseases

Country Status (3)

Country Link
EP (1) EP1357914A2 (en)
AU (1) AU2002243778A1 (en)
WO (1) WO2002070011A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336532C1 (en) 2001-09-14 2008-10-16 Amgen, Inc Linked biaryl compounds
KR100474202B1 (en) * 2002-05-04 2005-03-08 강헌중 Process for preparing thiazol derivative and the intermediate compounds for preparing the same
DE602005024384D1 (en) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc NEW COMPOUNDS, ITS MANUFACTURE AND USE
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2449618T3 (en) 2005-06-30 2014-03-20 High Point Pharmaceuticals, Llc Phenoxyacetic acids as activators of PPAR-delta
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
EP1023907A1 (en) * 1997-07-24 2000-08-02 Yamanouchi Pharmaceutical Co. Ltd. Medicinal compositions with cholesterol-lowering effect
WO2001000603A1 (en) * 1999-06-25 2001-01-04 Glaxo Group Limited Thiazole and oxazole derivatives and their pharmaceutical use
WO2001007066A2 (en) * 1999-07-23 2001-02-01 The University Of Dundee Ppar delta inhibitors for the treatment of cardiovascular diseases
WO2001034200A1 (en) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd Body weight gain inhibitors
WO2001066098A2 (en) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Therapeutic uses of ppar mediators
WO2001079197A1 (en) * 2000-04-14 2001-10-25 Nippon Chemiphar Co.,Ltd. ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)
WO2002007765A2 (en) * 2000-07-20 2002-01-31 Bristol-Myers Squibb Company REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE
WO2002014291A1 (en) * 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. PPARδ ACTIVATORS
WO2002028434A2 (en) * 2000-10-05 2002-04-11 Glaxo Group Limited Use of a ppar delta activator for treating inflammatory conditions
WO2002046154A1 (en) * 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Peroxisome proliferator activated receptor d activators

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
EP1023907A1 (en) * 1997-07-24 2000-08-02 Yamanouchi Pharmaceutical Co. Ltd. Medicinal compositions with cholesterol-lowering effect
WO2001000603A1 (en) * 1999-06-25 2001-01-04 Glaxo Group Limited Thiazole and oxazole derivatives and their pharmaceutical use
WO2001007066A2 (en) * 1999-07-23 2001-02-01 The University Of Dundee Ppar delta inhibitors for the treatment of cardiovascular diseases
WO2001034200A1 (en) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd Body weight gain inhibitors
WO2001066098A2 (en) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Therapeutic uses of ppar mediators
WO2001079197A1 (en) * 2000-04-14 2001-10-25 Nippon Chemiphar Co.,Ltd. ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)
WO2002007765A2 (en) * 2000-07-20 2002-01-31 Bristol-Myers Squibb Company REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE
WO2002014291A1 (en) * 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. PPARδ ACTIVATORS
WO2002028434A2 (en) * 2000-10-05 2002-04-11 Glaxo Group Limited Use of a ppar delta activator for treating inflammatory conditions
WO2002046154A1 (en) * 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Peroxisome proliferator activated receptor d activators

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A. BROOKS-WILSON ET AL: "Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency", NATURE GENETICS, vol. 22, August 1999 (1999-08-01), pages 336 - 345, XP002215795 *
BODZIOCH MAREK ET AL: "The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 22, no. 4, August 1999 (1999-08-01), pages 347 - 351, XP000889766, ISSN: 1061-4036 *
DATABASE WPI Section Ch Week 200141, Derwent World Patents Index; Class B05, AN 2001-389756, XP002215800 *
DATABASE WPI Section Ch Week 200203, Derwent World Patents Index; Class B02, AN 2002-026000, XP002215799 *
DATABASE WPI Section Ch Week 200237, Derwent World Patents Index; Class B03, AN 2002-339438, XP002215797 *
DATABASE WPI Section Ch Week 200255, Derwent World Patents Index; Class B02, AN 2002-519654, XP002215798 *
M. D. LEIBOWITZ ET AL.: "Activation of PPARdelta alters lipid metabolism in db/db mice", FEBS LETTERS, vol. 473, 2000, pages 333 - 336, XP004337162 *
S. M. CLEE ET AL: "Age and residual cholesterol efflux affect HDl cholesterol levels and coronary artery disease in ABCA1 heterozygotes", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 106, no. 10, October 2000 (2000-10-01), pages 1263 - 1270, XP002215796 *
S. RUST ET AL: "Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1", NATURE GENETICS, vol. 22, August 1999 (1999-08-01), pages 352 - 355, XP002215794 *
SCHMITZ G ET AL: "ABC TRANSPORTERS IN CELLULAR LIPID TRAFFICKING", CURRENT OPINION IN LIPIDOLOGY, LONDON, GB, vol. 11, October 2000 (2000-10-01), pages 493 - 501, XP000992248, ISSN: 0957-9672 *
WILLSON T M ET AL: "The PPARs: From orphan receptors to drug discovery", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 4, 24 February 2000 (2000-02-24), pages 527 - 550, XP002158740, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
AU2002243778A1 (en) 2002-09-19
WO2002070011A2 (en) 2002-09-12
EP1357914A2 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP2537524A3 (en) Treatment of T-cell mediated diseases
DE60233801D1 (en) METHOD FOR TREATING JOINT IGNITION, PAIN AND MOBILITY LOSS
ATE472325T1 (en) INTRACORPORAL MEDICATIONS FOR THE PHOTODYNAMIC TREATMENT OF DISEASES
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
NO20034056D0 (en) Proliferative diseases
IL162505A0 (en) Method for treatment of peripheral neural and vascular ailments
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
EP1423537A4 (en) Compositions and methods for the prevention and treatment of huntington's disease
WO2004028570A3 (en) A method for treating severe tinnitus
WO2006002437A3 (en) Treatment of conditions involving demyelination
WO2003049717A3 (en) Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
EE200300559A (en) Use of Osteopontin for the treatment and / or prevention of neurological disorders
WO2003006893A3 (en) Methods of inhibiting amyloid toxicity
ATE319439T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE TRACHEO-BRONCHIAL TRACT, IN PARTICULAR COPD
WO2002070011A3 (en) Treatment of ppar mediated diseases
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
EP1500401A4 (en) Drugs for treating vascular diseases
HK1064261A1 (en) Method for the treatment of tobacco.
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004091436A3 (en) Methods and compositions for treating ocular disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10470886

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002709285

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002709285

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP